Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.30 USD

76.30
451,069

+1.53 (2.05%)

Updated Aug 4, 2025 04:00 PM ET

Pre-Market: $76.23 -0.07 (-0.09%) 8:01 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business and momentum in ProCyte One expansion.

Zacks Equity Research

Chemed's (CHE) VITAS Performance Aids, Macro Issues Linger

by Zacks Equity Research

Chemed (CHE) believes Roto-Rooter is well-positioned for growth and anticipates continued expansion of the segment's market share.

Zacks Equity Research

Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Zacks Equity Research

QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research

by Zacks Equity Research

QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by upcoming innovative launches, including Mobi and the new integrated CGM offering.

Zacks Equity Research

Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays

by Zacks Equity Research

QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.

Zacks Equity Research

Haemonetics (HAE) Q2 Earnings Top Estimates, 2024 View Up

by Zacks Equity Research

The robust volume growth and price benefits in the Plasma business driven by strong momentum in U.S. collections and price benefit Haemonetics' (HAE) fiscal second-quarter results.

Zacks Equity Research

Compared to Estimates, Haemonetics (HAE) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Shaun Pruitt headshot

3 Medical Products Stocks to Consider as Earnings Approach

by Shaun Pruitt

These top-rated Zacks Medical sector stocks are very attractive ahead of their quarterly reports on Thursday, November 2 with now looking like an ideal time to invest.

Zacks Equity Research

Haemonetics (HAE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Haemonetics (HAE) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and Haemonetics (HAE) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.

Zacks Equity Research

Quest Diagnostics (DGX) Gains From New Alliances Amid FX Woes

by Zacks Equity Research

Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.

Zacks Equity Research

Align (ALGN) Gains From New Launches, Strategic Partnerships

by Zacks Equity Research

Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.

Zacks Equity Research

STERIS' (STE) Improved Volume, New Buyouts Drive Growth

by Zacks Equity Research

On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.

Zacks Equity Research

Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft

by Zacks Equity Research

Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.

Zacks Equity Research

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.

Zacks Equity Research

Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod

by Zacks Equity Research

Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.

Zacks Equity Research

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher (TMO) due to its impressive acquisition deals and end-market strength.

Zacks Equity Research

Globus Medical (GMED) Gains From NuVasive Buyout, Innovation

by Zacks Equity Research

Globus Medical (GMED) is particularly seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Zacks Equity Research

Labcorp (LH) Launches Biomarker Test for Alzheimer's Disease

by Zacks Equity Research

Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.

Zacks Equity Research

Alcon (ALC) Gains From Growing Market Demand, New Launches

by Zacks Equity Research

Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.

Zacks Equity Research

ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch

by Zacks Equity Research

ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.